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A compromised brain reward system has been postulated as a key feature of drug depen-
dence. We examined whether several polymorphisms of genes found to regulate nicotinic
acetylcholine receptor (nAChR) and dopamine expression were related to an intrinsic
reward sensitivity (IRS) deficit we previously identified among a subgroup of smokers using
event-related potentials (ERPs).We examined genetic polymorphisms within the CHRNA5-
A3-B4 gene cluster (CHRNA3 rs578776, CHRNA5 rs16969968, LOC123688 rs8034191,
and CHRNA3 rs1051730), the ANKK1 gene (rs1800497), and the D2 dopamine receptor
gene (DRD2 rs1079597, DRD2 rs1799732) from 104 smokers of European ancestry in a
smoking cessation trial. Prior to treatment, we recorded ERPs evoked by emotional (both
pleasant and unpleasant), neutral, and cigarette-related pictures. Smokers were assigned
to two groups (IRS+/IRS−) based on the amplitude of the late positive potential (LPP)
component to the pictures, a neural marker of motivational salience. Smokers (n=42)
with blunted brain responses to intrinsically rewarding (pleasant) pictures and enhanced
responses to cigarette pictures were assigned to the IRS− group, while smokers (n=62)
with the opposite pattern of LPP responding were assigned to the IRS+ group. Carriers
of the protective minor T allele (T/T, C/T) of the CHRNA3 rs578776 were less likely to
be members of the IRS− group than those homozygous for the at-risk C allele (C/C). The
CHRNA3 rs578776 polymorphism did not differ on questionnaires of nicotine dependence,
depressed mood, or trait affective disposition and did not predict abstinence at 6 months
after the quit date.These results suggest that polymorphisms of genes influencing nAChR
expression are related to an endophenotype of reward sensitivity in smokers.
Keywords: nAChR, DRD2, nicotine, reward sensitivity, ERP, LPP, smoking cessation, genetics
INTRODUCTION
A compromised brain reward system has been postulated as a
key feature of drug dependence. Volkow and Colleagues (1–3)
proposed that, due to the supraphysiological dopamine (DA)
release in the midbrain resulting from drug use, addiction leads
to overvaluing drug-related stimuli and to undervaluing intrin-
sically rewarding stimuli (e.g., food, sex), a condition we refer to
as reduced intrinsic reward sensitivity (IRS−). The evidence for
this differential salience is mixed. While many studies have found
evidence for the enhanced motivational salience of drug-related
stimuli among the drug dependent compared to controls (4–7),
not all do (8, 9). Few studies have examined whether there is
a concomitant reduction in the salience of intrinsically reward-
ing stimuli among the drug dependent. Of those that have, some
have found that the drug dependent show enhanced salience to
drug stimuli and reduced salience to intrinsically rewarding stim-
uli compared to controls (10–12), though other findings in the
animal (13, 14) and human (15–17) literatures are equivocal.
Recently, using event-related potentials (ERPs), we found that
smokers who demonstrated IRS− were more likely to relapse
following a smoking cessation intervention than smokers with
“normal” intrinsic reward sensitivity [IRS+; (18)]. We identi-
fied this endophenotype by analyzing smokers’ ERP differences
to motivationally relevant visual stimuli. Baseline brain responses
to unpleasant, neutral, pleasant, and cigarette-related (CIG) pic-
tures were measured using the late positive potential (LPP). The
LPP is an ERP component that peaks between 400 and 700 ms
after stimulus onset and reliably indexes the motivational salience
of passively viewed affective pictures (19–23). Consistent with the
idea that after repeated drug use drug-related cues acquire moti-
vational significance (2, 3, 24), smokers produce LPP responses
to CIG pictures that are larger than those to neutral pictures (16,
25–27). However, by grouping smokers using individual patterns
of brain reactivity, we discovered that while all smokers show
larger LPP responses to cigarette than to neutral stimuli, a siz-
able number of them (45% of our sample) also show blunted
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brain responses to pleasant stimuli. Importantly, these individ-
ual differences in responsivity to pleasant stimuli predict subse-
quent smoking abstinence, such that smokers with blunted brain
responses to intrinsically pleasant stimuli (IRS−) had significantly
lower rates of long-term smoking abstinence than smokers with
normal responses to pleasant stimuli (IRS+).
Our findings suggest that a large portion of smokers have
blunted brain responses to intrinsically rewarding stimuli, but it is
unclear why certain smokers have this presumed deficit while oth-
ers do not. Genetic factors, particularly those that influence and
regulate DA-mediated reward signaling, are likely targets. While
nicotine dependence involves numerous neuroadaptations, the
binding of nicotine to nicotinic acetylcholine receptors (nAChRs)
on dopaminergic neurons in the ventral tegmental area (VTA) is
thought to be key to nicotine’s effects on motivation (28). Nico-
tine binding on VTA dopaminergic neurons leads to increased DA
burst firing, resulting in DA release in the outer shell of the nucleus
accumbens (NAcc), a part of the mesolimbic reward pathway (29).
One possible source for this IRS− endophenotype is reduced
striatal D2 DA receptor (D2R) density. A model that links stri-
atal D2R deficits, D2 dopamine receptor (DRD2) (and ANKK1)
genes, and substance abuse is the “reward deficiency syndrome”
(RDS) model by Blum and Colleagues (30, 31). In the RDS model,
individuals with deficits in DRD2 receptor genes experience less
reward and enjoyment from day-to-day activities (i.e., anhedo-
nia) and are prone to substance dependence to increase DA levels
and hedonic tone. The RDS model predicts that those with D2R
deficits should experience greater enjoyment of drugs that stim-
ulate DA release, which has been largely supported. For example,
among drug-naive individuals, those with the lower striatal D2R
density were more likely to report enjoying the novel effects of the
psychostimulant methylphenidate (32, 33) compared with those
with higher levels. However, research involving participants with
chronic mental illness suggest that D2R deficits do not result in
anhedonia, as suggested by the RDS model, but instead result in
affective flattening (34, 35). Affective flattening is thought to reflect
a reduction in the incentive salience of intrinsically pleasant stim-
uli and is consistent with the Incentive Salience model’s concept of
“wanting” (24). This increase in drug reinforcement and decrease
in responding to intrinsically rewarding cues appears to map onto
the IRS− endophenotype and led us to examine whether genes that
inform D2R expression could explain the differences we found.
The DRD2 gene and the adjacent ANKK1 gene have been linked
to D2R deficits, nicotine dependence, and reward sensitivity. The
DRD2 gene is located on chromosome 11q22–q23 and three of
the more frequently studied polymorphisms in the addictive dis-
orders have been the ANKK1 rs1800497, DRD2 rs1799732 (−141C
Ins/Del), and DRD2 rs1079597 (TaqI-B). The ANKK1 rs1800497,
formerly known as the DRD2 TaqI-A, is a protein kinase gene
located 9.5-kb downstream from the DRD2 locus on chromosome
11 (36). Those carrying the T (A1) allele have fewer striatal D2R
receptors compared to those without the T allele (37). The dele-
tion variant of the DRD2 rs1799732, located in the 5′ promoter
region, has been associated with lower promoter activity (38). The
biological significance of the DRD2 rs1079597, located in intron 1,
913 bp from the exon 2 start codon, is unknown (39). The ANKK1
rs1800497 has been linked to nicotine dependence in some (40,41),
but not all (42), studies. The ANKK1 rs1800497, DRD2 rs1079597,
and DRD2 rs1799732, have been found to predict the severity of
smoking withdrawal (43, 44) and to moderate the effects of bupro-
pion (45, 46) and nicotine replacement therapy [NRT; (46, 47)]
on smoking cessation, though recent work has either failed to find
a relationship between the ANKK1 rs1800497 and smoking cessa-
tion outcome (42) or found a relationship with cessation only in
subgroups such as women (48) or the depressed (49). In terms of
the brain’s reward system, the ANKK1 rs1800497 has been found
to be related to smoking enjoyment (50) and to smoking with the
intent of reducing negative affect (51), suggesting that it directly
affects nicotine reinforcement.
Striatal DA functioning is impacted by nicotine (52) through
its high affinity for α4β2-containing nAChRs in the VTA (53).
Activation of the α3 (54), α4 (55), α6 (56), α7 (57), and β2
(58) nAChR subunits has been found to enhance nicotine rein-
forcement. In terms of intrinsic reward sensitivity (IRS), nicotine
exposure has been found to lower the threshold for intrinsic reward
for at least 30 days in rodents (59). In humans, indirect evidence
comes from a study that found that schizophrenic smokers with
greater baseline symptoms of affective flattening were more likely
to benefit from treatment by varenicline, an α4β2 nAChR par-
tial agonist, benefits that included increased abstinence and larger
increases in reward sensitivity (60). The nAChR genes that have
been most associated with smoking in many population stud-
ies are the CHRNA5-A3-B4 gene cluster located on chromosome
15q25.1. The CHRNA5 rs16969968 (a non-synonymous coding
SNP in exon 5), the CHRNA3 rs578776 (3′ UTR), the CHRNA3
rs1051730 (a synonymous SNP in exon 5), and the rs8034191
(located in intron 2 of hypothetical gene LOC123688) are located
in a region of strong linkage disequilibrium (LD) and have been
found to be related to smoking and smoking heaviness (61–
63). The CHRNA5 rs16969968, the CHRNA3 rs578776, CHRNA3
rs1051730, and the LOC123688 rs8034191 have all been found
to be related to smoking rate and other measures of nicotine
dependence (61–63). While none of the CHRNA5-A3-B4 genetic
subunits have been shown to directly influence functioning of
the VTA or other areas associated with the brain’s reward system,
recent evidence from transgenic mice found that overexpressing
the human CHRNA5/A3/B4 gene cluster led to increased nico-
tine self-administration (64), suggesting a direct link between this
cluster and nicotine reinforcement.
In the present study, we investigated whether DRD2 and nAChR
genetic variants known to influence striatal DA functioning and
smoking behavior accounted for the reward sensitivity endophe-
notype we recently identified in smokers (18). We examined the
relationship between this IRS endophenotype, comprised of ERP
measures of motivational salience, and genetic polymorphisms
within the CHRNA5-A3-B4 gene cluster (CHRNA3 rs578776,
CHRNA5 rs16969968, LOC123688 rs8034191, and CHRNA3
rs1051730), the ANKK1 gene (rs1800497), and the D2 receptor
gene (DRD2 rs1799732, DRD2 rs1079597), from 104 smokers of
European ancestry in a smoking cessation trial [ClinicalTrials.gov
Identifier: NCT00507728; (65)]. We hypothesized that smokers
carrying at-risk nAChR, ANKK1, or D2 receptor alleles (i.e., alleles
previously linked to smoking behavior and nicotine dependence)
would be more likely to be in the IRS− group, as assessed by ERP
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to motivational stimuli, compared to those without these alleles.
We also assessed the incremental impact of possessing multiple at-
risk alleles on our ability to predict IRS group membership, using
receiver–operator curve (ROC) analysis.
MATERIALS AND METHODS
PARTICIPANTS
We recruited smokers from the community who were seeking to
quit smoking. Inclusion criteria included being aged 18–65 years,
smoking five or more cigarettes per day, producing a baseline
expired carbon monoxide (CO) level ≥6 ppm, having fluency
in English, and having a working telephone. Conditions that
excluded participants included taking psychotropic medication,
having a current psychiatric disorder (including substance abuse
or dependence, other than nicotine dependence), being involved
in any smoking cessation activities (e.g., NRT, counseling) except
those provided by the clinical trial, having contraindications for
either bupropion or varenicline, or having any uncontrolled med-
ical illness. Psychiatric disorders were assessed using the Mini-
International Neuropsychiatric Interview (66). Of the 294 enrolled
in the clinical trial (65), 208 eligible participants completed a base-
line laboratory ERP session, but only 180 yielded usable ERP data
and were included in our previous report describing the rein-
forcement sensitivity construct (18). A total of 24 were excluded
because of poor recording quality and 4 because of technical errors.
Of those 180 from our previous study, 104 were of self-reported
European ancestry and subject to the analyses described herein
(data from the 49 participants of African ancestry differed signifi-
cantly from those of European ancestry on several of the genotype
frequencies and were excluded from further analyses). Partici-
pants provided written informed consent, and the protocol and
informed consent document were approved by The University of
Texas MD Anderson Cancer Center Institutional Review Board.
PROCEDURES
Participants were screened for eligibility a week before the base-
line laboratory session. Participants were instructed to smoke
ad libitum before the baseline laboratory session. At the base-
line laboratory session, participants provided an expired carbon
monoxide (CO) sample, provided a buccal sample, and com-
pleted questionnaires including the Fagerström Test for Nicotine
Dependence [FTND; (67)], the Wisconsin Inventory of Smoking
Dependence Motives [WISDM; (68)], the Center for Epidemi-
ologic Studies Depression Scale [CES-D; (69)], the Depression
Proneness Inventory [DPI; (70)], the Behavioral Inhibition Sys-
tem/Behavioral Activation System (BIS/BAS) scales (71) and the
Fawcett–Clark Pleasure Scale [FCPS; (72)]. Next, the participants
had the electroencephalogram (EEG) electrodes applied and were
instructed to keep their eyes on the screen during the picture-
viewing task, to move as little as possible, and to ignore the
intermittent auditory startle probe noises delivered through the
earphones during the picture viewing.
Picture-viewing task
During the 30-min picture-viewing task, participants viewed 1 of
3 picture sets composed of 4 picture categories, including pleasant
(PLE), unpleasant (UNP), CIG, and neutral (NEU), with 24 pic-
tures in each category (96 total pictures per set). The three picture
sets were comprised of pictures from the International Affective
Picture System (IAPS) (73), the International Smoking Image
Series (ISIS) (74), and the Normative Appetitive Picture System
(NAPS) (75). We supplemented these sets using pictures gener-
ated by our laboratory, some of which were previously published
(76). Each set of 96 pictures included 24 pictures in 4 categories
(PLE, UNP, NEU, CIG). Each picture category included 16 pic-
tures depicting human beings and 8 without a person. In terms
of semantic content, the PLE category was comprised of erotic
couples (high arousal), romantic couples (low arousal), and pleas-
ant objects (e.g., food, landscapes; low arousal), UNP category
of mutilations (high arousal), sad scenes (e.g., grief, disease; low
arousal), and unpleasant objects (e.g., pollution, accidents; low
arousal), NEU category of neutral people and objects (e.g., house-
hold objects), and the CIG category of people smoking and CIG
objects (e.g., lit cigarettes in ashtrays). The arousal ratings of the
PLE and UNP pictures, which were primarily taken from the IAPS
set (see Table 1), are from published IAPS normative ratings (73).
Pictures were presented for 4 s, separated by a random inter-trial
interval of 3–5 s, in pseudo-random sequences with no more than
two pictures of the same category presented consecutively. Each
picture was presented twice during the session to increase the ERP
signal-to-noise ratio. Six (25%) the 24 pictures in each category
included a 50-ms 100 dB (A) white noise auditory startle probe that
occurred between 2.5 and 3.5 s after picture onset. These probes
occur substantially after the ERP component of interest here (400–
700 ms) and as such did not impact the ERPs to the pictures and
hence are not discussed in this report. Stimuli were presented with
a Pentium 4 computer using E-prime software (v1.4; Psychology
Software Tools, Inc., Pittsburgh, PA, USA) on a plasma screen
placed approximately 1.5 m from the participant’s eyes. The entire
picture-viewing session lasted approximately 30 min.
ERP data collection and scoring
Details of the EEG collection, offline scoring, and cluster analysis
are reported in Versace et al. (18) and summarized here. We col-
lected EEG during the picture-viewing task using a 129-channel
EEG net and AC-coupled high-input impedance (200 MΩ) ampli-
fier (Geodesic EEG System 200, Electrical Geodesics Inc., Eugene,
OR, USA) referenced to the Cz electrode site. EEG was sampled at
250 Hz and filtered online using 0.1-Hz high-pass and 100-Hz low-
pass filters, and the scalp impedance of each sensor was brought
below 50 kΩ, as suggested by the manufacturer.
Offline scoring included the following procedures: (1) applica-
tion of a 30-Hz low-pass filter; (2) visual inspection of the data,
with channels contaminated by artifacts for more than 50% of
the recording interpolated using spherical splines; (3) applica-
tion of a spatial filtering method (77) to correct for eye blinks;
(4) re-referencing to the average reference (78); (5) segmentation
of the EEG data using a 900-ms epoch with a 100-ms baseline
preceding the picture; (6) removal of segments if more than
10% of the sensors were contaminated by artifacts, defined as
EEG amplitude above 100 or below −100 mV, voltage difference
between any two adjacent samples larger than 100 mV, voltage dif-
ference between two adjacent samples above 25 mV, or variation of
<0.5 mV for more than 100 ms; (7) calculation of the mean LPP
amplitude between 400 and 700 ms after picture onset for each
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Table 1 | List of pictures used in the picture-viewing task, by picture category and source.
Source PLE UNP NEU CIG
IAPS 2208, 4599, 4610, 4611, 4623,
4624, 4625, 4626, 4640,
4641, 4643, 4645, 4647,
4649, 4650, 4653, 4658,
4659, 4660, 4666, 4669,
4676, 4677, 4680, 4687, 4689,
4690, 4691, 4693, 4694,
4695, 4696, 4698, 4700,
4800, 4810, 5250, 5626,
5628, 5629, 5631, 5660,
5661, 5700, 5711, 5764,
5780, 5781, 7270, 7330,
7340, 7350, 7410, 7430, 7450,
7460, 7470, 7480, 7482, 7485
2095, 2141, 2205, 2276, 2399,
2455, 2490, 2491, 2520, 2590,
2700, 2703, 2800, 2810, 2900,
3000, 3030, 3051, 3053, 3060,
3068, 3069, 3080, 3100, 3101,
3102, 3110, 3120, 3130, 3140,
3168, 3170, 3225, 3261, 3280,
3300, 3350, 6000, 6020, 6190,
6200, 6210, 6230, 6260, 6410,
9010, 9090, 9110, 9190, 9253,
9265, 9290, 9300, 9301, 9320,
9373, 9390, 9410, 9420, 9421,
9429, 9433, 9520, 9530, 9560,
9600, 9620, 9621, 9901, 9911,
9912, 9926
2102, 2104, 2190, 2191, 2200,
2210, 2214, 2215, 2220, 2221,
2230, 2235, 2305, 2312, 2358,
2372, 2383, 2393, 2396, 2397,
2435, 2441, 2485, 2493, 2495,
2499, 2500, 2510, 2512, 2513,
2515, 2570, 2575, 2579, 2593,
2594, 2595, 2597, 2598, 2600,
2630, 2830, 2850, 7000, 7002,
7004, 7006, 7009, 7010, 7020,
7030, 7034, 7038, 7040, 7041,
7052, 7053, 7054, 7055, 7056,
7059, 7080, 7090, 7110, 7130,
7140, 7550, 9070
ISIS 001, 003, 004, 007, 008, 010, 016,
017, 019, 020, 022, 029, 030, 031,
033, 034, 038, 047, 055, 058, 062,
063, 068, 070, 073, 081, 088, 089,
091, 092, 093, 097, 099, 100, 101,
103, 104, 106, 107, 108, 111, 115,
116, 118, 120
NAPS 101, 106
Internal (12 Pictures) (0 Pictures) (4 Pictures) (25 Pictures)
IAPS, International Affective Picture System (73); ISIS, International Smoking Image Series (74); NAPS, Normative Appetitive Picture System (75).The internal pictures
were generated by our laboratory, some of which were previously published (76), and are available upon request.
category (UNP, NEU, PLE, CIG) for each participant by averag-
ing over 10 sensors in the central and parietal regions with the
largest LPP differences between neutral and motivationally rel-
evant (UNP/PLE/CIG) pictures. We analyzed the LPP within the
400- to 700-ms time window because it is considered the time win-
dow within which the LPP differences among categories peak and
it is routinely used in studies investigating ERP responses to emo-
tional and neutral stimuli (21, 22, 79–81). Moreover, increasing the
length of the time window would have increased the number of
epochs discarded because of the presence of artifacts, which could
have reduced the reliability of the results without significantly
improving the power to detect differences among the stimuli.
ERP cluster analyses
Details of the LPP cluster analysis are reported in Versace et al.
(18). The four category LPP means from each participant were
entered into a cluster analysis (k-means method) to assign smok-
ers to two groups (IRS group) based on their brain responses to
the experimental visual stimuli. Cluster analysis is a group of mul-
tivariate techniques whose purpose is to assemble objects (i.e.,
participants) based on the response patterns of several character-
istics (82). A two-cluster solution was selected a priori because
we hypothesized that smokers would differ on the basis of their
sensitivity to intrinsically pleasant stimuli, which resulted in 99
participants assigned to Cluster 1 and 81 participants to Cluster
2. To evaluate if the two-cluster solution was appropriate, we used
Euclidean distances and the Hartigan and Wong (83) algorithm
for solutions ranging from 2 to 15 clusters. The Cubic Clustering
Criterion (84) and the Duda–Hart Index (85), two commonly used
stopping rules for iterative clustering, both indicated that the two-
cluster solution was optimal. We next conducted an ANOVA using
cluster (Cluster 1 vs. 2) as a between-subjects factor and picture
type (UNP, NEU, PLE, CIG) as a within-subjects factor and found
a significant two-way interaction, F(3,534)= 43.49, p< 0.0001.
Post hoc contrasts indicated that LPP to pleasant pictures were
significantly smaller in Cluster 2 (M = 1.76 SE = 0.17) than in
Cluster 1 (M = 2.95, SE= 0.16; p< 0.0001), but that CIG pictures
were somewhat larger LPP in Cluster 2 (M = 2.47, SE= 0.16) than
in Cluster 1 (M = 1.81, SE= 0.15; p< 0.10). The two clusters did
not differ on LPPs to either neutral or unpleasant pictures. We
refer to Cluster 1 as the “normal” IRS cluster (IRS+) and Cluster
2 as the reduced IRS cluster (IRS−).
Genotyping
Genomic DNA was extracted from buccal cells by using the
QIAmp DNA kit (cat. # 51185; QIAGEN Sciences, Valencia, CA,
USA). Single nucleotide polymorphism genotyping of the DA
and nAChR SNPs was performed using the 5′ nuclease assay
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to discriminate between the two alleles representing the dif-
ferent genotypes. The assay reagents for SNP genotyping con-
sisted of a mix of PCR primers and TaqMan MGB probes
(FAM and VIC labeled) that were obtained from Applied
Biosystems (Foster City, CA, USA). TaqMan SNP Genotyp-
ing Assays (ABI) were used for the polymorphisms ANKK1
rs1800497 (C_7486676_10), DRD2 rs1079597 (C_2278884_10),
CHRNA5 rs16969968 (C_26000428_20), CHRNA3 rs578776
(C_721253_10), CHRNA3 rs1051730 (C_9510307_20), and
LOC123688 rs8034191 (C_479126_10). Probes and primer for the
DRD2 rs1799732 polymorphism were designed in-house (Probe
1: FAMTACCCGTTCCAGGCCMGBNFQ; Probe 2: VICTACC-
CGTTCAGGCCGMGBNFQ; Primer 1: AAACAAGGGATGGCG-
GAAT; Primer 2: CCCCACCAAAGGAGCTGTA). Each assay
enables scoring of both alleles in a single well within a 384-well
plate. All assays are optimized to work with genomic DNA and Taq-
Man Universal Master Mix from Applied Biosystems. Forty cycles
of PCR were performed. Plates were analyzed using an ABI Prism
7900HT Sequence Detection System from Applied Biosystems.
Statistical analysis
The tests of Hardy–Weinberg Equilibrium (HWE) and LD, and
frequencies by allele and genotype, were completed using SAS
Proc Allele (v9.2; SAS Institute, Carey, NC, USA). We used chi-
square tests to examine dominant (homozygous wild type vs.
heterozygotes and homozygous variants) and recessive (homozy-
gous variant vs. heterozygotes and homozygous wild type) models
of gene action on IRS group membership, with the interpretation
of statistical significance adjusted for multiple comparisons using
the Bonferroni correction. We used t -tests to evaluate differences
in baseline measures by genotype and IRS group, with Satterth-
waite’s approximation for degrees of freedom when variance was
unequal.
RESULTS
ALLELE AND GENOTYPE FREQUENCIES
The tests of HWE and LD, and frequencies by allele and geno-
type for the participants of European ancestry are reported in
Table 2. The frequencies of the DRD2 rs1079597 (TaqI-B) and
DRD2 rs1799732 (−141C Ins/Del) did not meet HWE criteria
but were included in further analyses for exploratory purposes.
In terms of LD, the CHRNA5 rs16969968, LOC123688 rs8034191,
CHRNA3 rs578776, and CHRNA3 rs1051730 SNPs were all found
to be in strong LD with each other (r range: 0.53–0.97). The DRD2
rs1079597 was in LD with the ANKK1 rs1800497, r = 0.96. The
CHRNB2 rs2072661 and DRD2 rs1799732 were not in LD with
the other SNPs.
BASELINE CHARACTERISTICS, BY IRS GROUP
For this sample of 104 smokers of European ancestry, we assigned
IRS group membership based on the cluster solution from our full
(n= 180) sample (18). We analyzed our baseline questionnaires
by IRS group, and found that IRS− smokers produced signifi-
cantly higher expired CO values than IRS+ smokers, Satterthwaite
t (60.43)= 2.03, p< 0.05 (see Table 3). The IRS groups did not
differ on any other measure.
Table 2 |Tests of Hardy–Weinberg equilibrium and frequencies by
allele and genotype for the participants of European ancestry.
Gene/SNP Frequency Hardy–Weinberg
equilibrium
Allele/genotype n % χ2 df pValue
ANKK1 rs1800497 0.00 1 1.00
T 48 25.0
C 144 75.0
T/T 6 6.3
T/C 36 37.5
C/C 54 56.3
DRD2 rs1079597 8.46 1 0.004
A 59 30.7
G 133 69.3
A/A 3 3.1
A/G 53 55.2
G/G 40 41.7
DRD2 rs1799732 5.46 1 0.05
Ins 171 90.0
Del 19 10.0
Ins/Ins 79 83.2
Ins/Del 13 13.7
Del/Del 3 3.2
CHRNA5 rs16969968 1.17 1 0.39
A 71 35.2
G 131 64.8
A/A 10 9.9
A/G 51 50.5
G/G 40 39.6
CHRNA3 rs1051730 0.57 1 0.52
A 71 35.9
G 127 64.1
A/A 11 11.1
A/G 49 49.5
G/G 39 39.4
CHRNA3 rs578776 1.23 1 0.26
T 45 22.5
C 155 77.5
T/T 7 7.0
C/T 31 31.0
C/C 62 62.0
CHRNB2 rs2072661 0.87 1 0.43
A 50 25.0
G 150 75.0
A/A 8 8.0
A/G 34 34.0
G/G 58 58.0
LOC123688 rs8034191 0.98 1 0.40
C 70 35
T 130 65
C/C 10 10
C/T 50 50
T/T 40 40
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Table 3 | Baseline demographics, smoking, and affective
characteristics, by IRS group (n=104).
IRS group
Characteristic IRS+ IRS−
n (%)
Total n 62 (59.6) 42 (40.4)
Female 17 (27.4) 16 (38.1)
Positive depression history 7 (11.3) 5 (9.5)
MEAN (SD)
Age 44.34 (11.2) 44.95 (10.6)
Years of smoking 24.60 (12.0) 26.67 (10.8)
Cigarettes/day 21.13 (8.4) 21.79 (8.1)
Expired CO (ppm) 23.85 (9.1) 29.21 (15.42)a
FTND score 4.71 (2.3) 5.19 (2.2)
WISDM (total score) 44.45 (10.2) 46.35 (9.3)
CES-D (total score) 7.52 (6.1) 7.57 (6.2)
Depression proneness inventory 2.61 (1.0) 2.70 (1.1)
Fawcett–Clark Pleasure Scale 3.68 (0.4) 3.74 (0.3)
BAS 26.97 (5.8) 28.50 (4.8)
BIS 14.89 (3.5) 15.17 (2.9)
aSignificant t-test comparison, by IRS group, at α<0.05 (uncorrected). CO, carbon
monoxide; FTND, Fagerström test for nicotine dependence; WISDM, Wisconsin
inventory of smoking dependence motives; CES-D, the center for epidemio-
logic studies’ depression scale; BAS, behavioral approach system; BIS, behavioral
inhibition system.
LPP AMPLITUDE, BY IRS GROUP AND PICTURE CATEGORY
To verify the differential responsivity by IRS group to cigarette
and pleasant pictures in the present sample, we conducted an
ANOVA on the 104 smokers of European ancestry using IRS
group [IRS+ (n= 62) vs. IRS− (n= 42)] as a between-subjects
factor, picture category (UNP, NEU, PLE, CIG) as a within-subjects
factor, and mean LPP amplitude (between 400 and 700 ms after
picture onset) as the dependent variable. We found a significant
main effect of picture category, F(4,415)= 20.98, p< 0.0001 (see
Figure 1), and two-way IRS group by picture category interaction,
F(3,408)= 15.52, p< 0.0001 (see Figure 2). Comparable to the
results from the full sample of 180 smokers (18), the post hoc con-
trasts for the 104 smokers of European ancestry indicated that LPPs
to pleasant pictures were significantly smaller in IRS− smokers
(M = 2.01µV, SD= 1.34), than in IRS+ smokers (M = 3.47µV,
SD= 1.67; p< 0.0001). LPPs to CIG pictures were somewhat
larger in IRS− (M = 2.66µV, SD= 1.27) than in IRS+ smokers
(M = 2.21µV, SD= 1.59), but the difference was not statistically
significant (p< 0.13). The two IRS groups did not differ on LPPs
to either neutral or unpleasant pictures. Covarying expired CO
did not alter the significant findings.
GENE BY IRS GROUP
The ORs and 95% CIs for IRS group membership by genotype
(dominance models) are depicted in Table 4. After correcting for
multiple comparisons, only the CHRNA3 rs578776 was signifi-
cant, with carriers of the protective minor T allele (T/T, C/T) less
likely to be in the IRS− group than those homozygous for the
FIGURE 1 |The significant picture category (UNP, NEU, PLE, CIG) main
effect on mean LPP amplitude for 104 smokers of European ancestry.
The error bars depict standard deviations. *Significantly different from NEU.
‡ Significantly different from PLE.
FIGURE 2 |The IRS group (IRS+ vs. IRS−) by picture category (UNP,
NEU, PLE, CIG) interaction on mean LPP amplitude. The error bars
depict standard deviations. *Significant pairwise comparison, p<0.0001.
at-risk C allele (C/C), OR= 0.17, 95% CI 0.07–0.46 (see Figure 3
for CHRNA3 rs578776 ERP waveforms). Carriers of the at-risk
T (A1) minor allele (T/T, T/C) of the ANKK1 rs1800497 were
more likely to be in the IRS− group than those homozygous for
the C (A2) allele (C/C), OR= 2.39, 95% CI 1.04–5.52, but this
difference was not significantly different after correcting for mul-
tiple comparisons. The CHRNA5 rs16969968’s relationship to IRS
group approached statistical significance prior to correcting for
multiple comparisons, OR= 2.26, 95% CI 0.97–5.24, suggesting
that carriers of the at-risk A minor allele (A/A, A/G) were more
likely to be in the IRS− cluster than those homozygous for the
G allele. The frequencies of the LOC123688 rs8034191, CHRNA3
rs1051730, DRD2 rs1079597, and DRD2 rs1799732 SNPs did not
significantly differ by IRS group.
To determine whether the at-risk alleles have an additive impact
on the prediction of IRS group membership, we examined the
incremental impact of the other polymorphisms we evaluated on
the CHRNA3 rs578776’s ability to predict IRS group membership,
using ROC analysis (86). As reported above, the presence of the
protective T allele decreased the odds of being in the IRS− group
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Table 4 | Chi-square analyses with dominance models (homozygous
wild type vs. heterozygotes and homozygous variants) predicting
reduced intrinsic reward sensitivity (IRS−membership), all df=1.
Polymorphism OR 95% CI χ2 Uncorrected p value
CHRNA3 rs578776 0.17 0.07–0.46 13.99 0.0002a
ANKK1 rs1800497 2.39 1.04–5.52 4.28 0.04
CHRNA5 rs16969968 2.26 0.97–5.24 3.66 0.06
CHRNA3 rs1051730 1.97 0.84–4.60 2.48 0.12
LOC123688 rs8034191 1.36 0.60–3.09 0.55 0.46
CHRNB2 rs2072661 0.90 0.40–2.01 0.07 0.80
DRD2 rs1079597 1.40 0.60–3.28 0.62 0.43
DRD2 rs1799732 1.23 0.41–4.14 0.14 0.71
aStatistically significant after correcting for multiple comparisons.
FIGURE 3 | Event-related potential waveforms, by picture category, for
CHRNA3 rs578776 (A) carriers of the protective minorT allele (T/T, C/T)
and (B) those homozygous for the at-risk C allele (C/C).
by a factor of 0.17 (OR= 0.17, 95% CI 0.07–0.46). This cor-
responded to an area under the curve (AUC) of 0.68. Adding
the ANKK1 rs1800497 and CHNRA3 1051730 polymorphisms,
as a block, incremented the fit of the model [∆χ2(2)= 6.32,
p< 0.04] and increased the AUC to 0.76. These results show that
the CHRNA3 rs578776 predicted the IRS endophenotype, and that
this prediction may be augmented by adding other SNPs associ-
ated with smoking behavior. Including the other polymorphisms
did not significantly increase the AUC.
PREDICTION OF ABSTINENCE
In the original sample of 180, we found that IRS group predicted
abstinence outcome (18), such that IRS− smokers quit smoking
less often than did IRS+ smokers. In the current sample of 104
smokers of European ancestry, we verified this relationship using
logistic models to compare the smoking abstinence rates of the
two IRS groups at 10 weeks, 3 months, and 6 months after the
quit date. In this reduced sample, IRS− smokers were also absti-
nent less often than IRS+ at 10 weeks (OR= 2.73, 95% CI 1.07–
6.91), 3 months (OR= 3.06, 95% CI 1.19–7.90), and 6 months
(OR= 4.03, 95% CI 1.37–11.88) after the quit date. There were
no significant relationships between any of the SNPs (domi-
nance models) and abstinence at 10-weeks (EOT), 3-months, or
6-months post-quit. There were also no significant interactions
between IRS group and SNPs when predicting abstinence at any
of the time points.
BASELINE MEASURES, BY GENOTYPE
To determine whether the participants differed on smoking or
affective disposition by genotype, we analyzed our baseline ques-
tionnaires by the dominance models for the polymorphisms that
differed by IRS group, the ANKK1 rs1800497 and the CHRNA3
rs578776, as well as the CHRNA5 rs16969968. No significant dif-
ferences (ps> 0.05) between genotype were found for any of the
baseline questionnaires.
DISCUSSION
These results support the hypothesis that genes associated with
nAChR activity are related to a novel neural marker of reward sen-
sitivity in smokers. Carriers of the protective minor T allele of the
CHRNA3 rs578776, a SNP in the CHRNA5-A3-B4 gene cluster on
chromosome 15, were significantly less likely to be among those
in the IRS− group. Though not statistically significant after cor-
recting for multiple comparisons, carriers of the at-risk ANKK1
rs1800497 T (A1) allele or the at-risk CHRNA5 rs16969968 A allele
were more likely to be among those in the IRS− group.
Our finding that the protective T allele of the CHRNA3
rs578776 polymorphism is associated with IRS+ smokers is con-
sistent with previous findings concerning the relationship between
that allele and nicotine dependence. The protective minor T
allele of the CHRNA3 rs578776 has been found to be associ-
ated with reduced risk for nicotine dependence in European-
Americans (87), but not African-Americans (88), and in smokers
who began daily smoking before the age of 17 (89). The pro-
tective minor T allele of the CHRNA3 rs578776 has also been
found to be protective against heaviness of smoking (61, 90).
In an fMRI study, the rs578776 at-risk C allele was associated
with increased activation in a circuit comprising the dorsal ante-
rior cingulate cortex and left anterior thalamus, a circuit that
may be sensitive to nicotine exposure or to the alleviation of
craving (91).
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Our results suggest that the CHRNA3 rs578776 T allele’s pro-
tective effect against smoking dependence may be due to its
association with normal reward sensitivity to intrinsically pleas-
ant activity in smokers. However, none of the baseline measures of
nicotine dependence, depressed mood, or trait affective disposi-
tion differed by CHRNA3 rs578776 genotype in the present study.
This is unsurprising given that none of these questionnaires dif-
fered by IRS group in this and the full samples (18). This suggests
that the IRS grouping represents a distinct endophenotype that is
not easily captured by self-report and that offers clinical utility as a
diagnostic marker of genetic and treatment risk. As we concluded
in our previous manuscript (18), this endophenotype could be
used to identify smokers who are at greater risk for relapse and
who may need cessation interventions tailored to address their
hyposensitivity to intrinsically reinforcing stimuli.
There were several null findings that were unexpected. First,
some of the polymorphisms most commonly associated with
smoking behavior, the ANKK1 rs1800497, CHNRA3 1051730, and
CHRNA5 rs16969968, were not significantly related to IRS group.
However, the at-risk alleles for these polymorphisms were associ-
ated with IRS−membership in the expected direction. They were
likely not significant due to inadequate statistical power to detect
their weaker effect size compare to that of the CHRNA3 rs578776.
Additionally, our ROC analysis found that the likelihood of IRS−
group membership significantly increases with possession of the
ANKK1 rs1800497 and CHNRA3 1051730 at-risk alleles, suggest-
ing that these polymorphisms are related to the endophenotype.
Second, none of the polymorphisms predicted abstinence out-
come, despite the significant associations between IRS group and
abstinence at 10-weeks (EOT), 3-months, and 6-months post-
quit. These findings are not necessarily inconsistent, because an
endophenotype such as IRS group membership is likely deter-
mined by multiple genetic and environmental factors, as is shown
by our ROC analysis.
Previous results largely support models of addiction that postu-
late that chronic drug use leads to overvaluing drug-related stimuli
and undervaluing intrinsically reinforcing stimuli due to the large
differential in DA enhancement between the two reinforcers (1–3).
However, in a previous study (18), we found that this change in
intrinsic reward valuation is not common to all chronic drug users.
Our current results suggest that the individual’s genetic profile
contributes to this variability. Our IRS endophenotype is consis-
tent with Blums’ RDS model (30, 31) in that a subset of smokers
appear to experience increased salience to drug-related stimuli and
decreased salience to intrinsically rewarding stimuli. The individ-
ual differences reflected in the IRS endophenotype could explain
the equivocal findings in the literature, with some (13, 15) but not
all (14, 92, 93) studies finding that chronic substance users over-
value the drug compared to natural reinforcers. However, we were
unable to conclusively link the IRS− deficit to the reduced D2R
density predicted by the RDS model because of the statistically
non-significant association between IRS group and the ANKK1
rs1800497 polymorphism.
These findings are tempered by several limitations of this study.
First, while the sample size was large for an ERP study, it was small
for a genetic association study. This may explain why two other
SNPs linked with smoking behavior, the ANKK1 rs1800497 and the
CHRNA5 rs16969968, produced results suggesting a link between
their at-risk variant and blunted brain responses to the intrinsi-
cally pleasant pictures that were statistically non-significant, after
a correction for multiple comparisons. However, this limitation
will likely confront any researcher who seeks to examine drug use
endophenotypes that are more complex than smoker/non-smoker
or nicotine dependence status. Second, we did not include a con-
trol group and only measured ERP during conditions of relative
nicotine satiation, at baseline. We were thus unable to determine
whether the reward system alterations we observed were spe-
cific to drug dependence or whether they would be exacerbated
by protracted withdrawal in this study, as is predicted by recent
addiction models [e.g., Ref. (2)]. Third, we were unable to sep-
arate out the pharmacological effects from the behavioral effects
of smoking on LPP response, an issue that could be addressed by
the use of blinded placebo cigarettes. Finally, it is possible that
these genotypes we identified are markers for individuals with
trait-level dysphoria or anhedonia, with smoking merely being a
means by which these individuals “self-medicate” for deficiencies
in their brain’s DA-mediated reward system (30). However, the
participants in our sample did not differ by genotype on several
questionnaire measures that are presumably sensitive to trait-level
differences in affective predisposition. Indeed, the lack of associa-
tion between the genotypes and our baseline measures of smoking
dependence and trait affective disposition strengthens the clinical
relevance of our IRS group measure and highlights the potential
relevance of the LPP grouping as an endophenotype for predicting
treatment response.
Future studies should examine whether the IRS− endophe-
notype is found among those with other drug abuse disorders
and those from a healthy population to determine the extent
to the IRS− endophenotype represents a risk factor specific to
addiction. The relationship between this endophenotype and the
development of nicotine dependence should be examined among
adolescents at risk for nicotine dependence. This endophenotype
should be replicated and extended by using imaging technology
to more precisely identify related regions of the brain. The rela-
tionship between IRS group and other endophenotypes related to
reward, such as impulsivity (94), should be investigated. Finally,
the relationship between the IRS group endophenotype and other
genetic polymorphisms related to the brain’s reward system and
nicotine dependence should be examined, including dopamine
D4 receptor (DRD4) (95) and DA transporter (SLC6A3) (96)
genes.
CONCLUSION
In conclusion, these results suggest that polymorphisms of genes
influencing nAChR expression are related to a neural marker of
reward sensitivity in smokers, a marker that may be a clinically
useful endophenotype for identifying smokers at risk for relapse.
In particular, the CHRNA3 rs578776 was found to predict mem-
bership in clusters that varied by reward sensitivity to natural
and cigarette stimuli and that predicted smoking cessation out-
come. These results suggest that an endophenotype comprised
of ERP measures of motivational salience can be a valuable tool
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for studying the interplay between drug dependence, genetics,
and brain alterations thought to maintain dependence and as a
diagnostic marker for identifying smokers who are at greater risk
for relapse and who may need cessation interventions tailored to
address their hyposensitivity to intrinsically reinforcing stimuli.
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